Advanced Urothelial Cancer
Cisplatin-based chemotherapy has historically been standard care for locally advanced or metastatic urothelial carcinoma. The treatment landscape for advanced urothelial cancer has changed because of immune checkpoint inhibitors, targeted…
1 sources - 4 claims
Cisplatin-based chemotherapy has historically been standard care for locally advanced or metastatic urothelial carcinoma. The treatment landscape for advanced urothelial cancer has changed because of immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates. Bladder urothelial carcinoma is the 11th most common cancer overall in the UK and the ninth leading cause of cancer-related death. Urothelial carcinoma is clinically and economically important in the UK.